返回列表 回复 发帖

版主

Rank: 7Rank: 7Rank: 7
1#
打印
tT
凤凰涅盘发表于 2011-12-17 17:50 | 只看该作者

Act公司 结算，代理，并展望未来

Settlements, Proxy, and Looking Ahead
http://www.thechairmansblog.com/ ... -looking-ahead.html

你无疑意识到，我们现在拥有的唯一区别是FDA批准的公司进行人体临床试验利用人类胚胎干细胞疗法。我们双方进行阶段1 /2试验使用人类胚胎干细胞（干细胞）源性视网膜色素上皮细胞（上皮）细胞，一为氏黄斑营养不良（贴片）和其他干年龄相关性黄斑变性（干和）。我们都很激动的初步结果从第一例经治疗后已在加州大学洛杉矶分校的朱勒眼科研究所，我们期待与世界分享更多细节在适当的时间和适当的战略
收藏 分享 评分
生命不息，战斗不止。
回复 引用

订阅 TOP

金牌会员

Rank: 6Rank: 6
2#
洁傲不逊发表于 2011-12-17 20:46 | 只看该作者
好消息 谢谢分享 不过ACT的官网现在正在维修 等待源文件 想仔细看看
回复 引用

TOP

金牌会员

Rank: 6Rank: 6
3#
muse发表于 2011-12-17 22:30 | 只看该作者
真是好消息 ，谢谢分享！
回复 引用

TOP

版主

Rank: 7Rank: 7Rank: 7
4#
flyeagle发表于 2011-12-18 09:40 | 只看该作者
好消息 ，谢谢楼主分享！
期待有一天能飞翔！
回复 引用

TOP

管理员

Rank: 9Rank: 9Rank: 9
5#
雪山飞狐发表于 2011-12-18 10:20 | 只看该作者
谢谢楼主的分享！

我更关心安全性，不知道美国的实验是做了一年以后公布结果就证明是安全的？还是需要长期的观察（3年以上）才通过实验？
回复 引用

TOP

版主

Rank: 7Rank: 7Rank: 7
6#
凤凰涅盘发表于 2011-12-18 10:58 | 只看该作者
2# 洁傲不逊

Greetings,

You have no doubt seen our recent 8K filing and press release about the settlements and the filing of the preliminary proxy.  In this blog post I would like to add a bit of color on these topics and also touch on other recent milestones, plans for the future, and give a run-down of our ocular programs, including some important but lesser-known ones.

As the press release about the settlements and proxy states, we have entered into settlement agreements with 40 holders of warrants and debentures.  There are a total of 48 holders of such warrants and debentures.  Of the eight not covered by these settlement agreements, we have been unable to reach four (which would total only 8.5 million shares in a settlement).  Of the four remaining, with whom we are in active litigation: two have already been granted shares by court orders; one is in advanced settlement discussions with us; and one remains a counterparty in as yet unresolved litigation.  We are pleased to have reached settlement agreements with the majority of holders and look forward to having all such matters behind us.  These settlements and the results of this litigation will result in the final resolution of the extraordinarily onerous anti-dilution provisions in the company’s debenture and warrant financings of the 2005 to early 2010 period.  I, for one, am thrilled to be putting this to rest.  The overhang that this created restricted so many of the company’s potential activities and corporate actions, and was a constant source of concern to us as we were always looking over our shoulders to see if we were creating additional potential liability.  It also resulted in wild quarterly swings in earnings, as the derivative liability caused by our stock price changes was accounted for in income statement gains or losses.

For our shareholders, I would like to stress the importance of the preliminary proxy.  As the release and filing mention, the record date is December 8, 2011 and the special meeting date is January 24, 2012.  I would like to emphasize again how important it is to vote “For” the increase in authorized shares, to complete the settlement agreement but also to enable the company to continue its R&D and clinical programs.  More on our programs is below, but I hope you will seriously consider an affirmative vote when you receive your proxy ballot in the mail.

I would also like to invite our shareholders to attend our Special Meeting at the Hyatt Regency Palm Springs.  I look forward to meeting some of you there in-person.

As mentioned, too, stockholders who have questions or need assistance should contact our proxy solicitor, InvestorCom, Inc., at 877-972-0090.

While we are putting these issues and challenges from the past firmly behind us, we are also proud to reflect on some recent achievements, as they help put us on very firm footing for a successful 2012 and beyond.

Notably, we recently appointed three new board members: Dr. Robert Langer, David H. Koch Institute Professor at MIT, whose appointment we announced in October; Zohar Loshitzer, CEO of Presbia, an opthalmic device firm; and Gregory D. Perry, EVP and CFO of ImmunoGen, a publicly-traded biotech firm with a market cap of over $900 million.  I really cannot overstate how pleased I am about these appointments.  Between the three of them, Bob, Zohar and Greg, respectively, bring a vast depth of experience in science, in commercializing emerging medical technologies, and in fundraising and partnering to the company at a critical juncture.  Last week, we had our first meeting of this new board.  The entire company leadership team gave presentations advising the board on scientific development opportunities and priorities, regulatory and clinical updates, manufacturing activities and plans, joint venture opportunities and the company’s first ever complete annual budget process.  The interplay between the board and the leadership team was incredibly productive, and would have made any shareholder proud of our activities.  We will be sharing summaries of these presentations with you early in 2012.

As you are no doubt aware, we now have the distinction of being the only company that is conducting FDA-cleared human clinical trials using human embryonic stem cell-derived therapies.  Both of our ongoing Phase 1/2 trials use human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells, one for Stargardt’s macular dystrophy (SMD) and the other for dry age-related macular degeneration (dry AMD).

We are very excited by the initial results from the first two patients that have been treated at UCLA’s Jules Stein Eye Institute, and we look forward to sharing more specifics with the world at the proper time and with the appropriate strategic approach, in coming weeks.  I know that many investors are in a rush for us to treat patients as quickly as possible, but we have quite good clinical, corporate and calendar-based reasons to be working on a more deliberate pace for the time being.

We also secured clearance from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to begin a similar clinical trial for SMD, which would be the first human embryonic stem cell trial in Europe.  We are currently on track to treat the first patient at Moorfields Hospital, perhaps the world’s foremost innovator in eye care, before the end of January.

Most of the company’s followers are already familiar with the RPE program described above. We are moving forward on a variety of research and development fronts, though, so I would like to briefly describe our other ocular programs:

Our hemangioblast program for generating hemangioblast cells to treat a wide variety of vascular and hematopoietic disorders is moving forward.  A hemangioblast is a multipotent cell that is a common precursor to both hematopoietic and endothelial cells.  The ability of these cells to promote angiogenesis (the growth of new blood vessels) has led us to successfully demonstrate that these cells promote revascularization in various models, including diabetic retinopathy.  In September we were awarded a patent for generating  and expanding hemangioblast cells from hESCs.

We have also developed a novel progenitor cell for protecting and replacing neurons in the visual field.  In animal models of photoreceptor degeneration, we have been able to show that these cells appear to activate regeneration and remodeling in response to disease or injury of the eye.  These cells could eventually be used as part of a therapy to address the neuronal loss resulting from glaucoma.
生命不息，战斗不止。
回复 引用

TOP

版主

Rank: 7Rank: 7Rank: 7
7#
凤凰涅盘发表于 2011-12-18 10:59 | 只看该作者
2# 洁傲不逊
Our corneal program continues to advance.  We are addressing the fundamental need for transplantable corneal tissue through readily manufacturable corneal tissues.

Finally, a program that has captured the imagination of a number of the scientist in our company comes from a fundamental new approach to generating robust mesenchymal, or multipotent, stem cells (MSCs).  Applied to our eye program, we expect to be able to use MSCs in the treatment of glaucoma and uveitis (inflammation in the middle layer of the eye, called the uvea), retinitis pigmentosa (describes a number of genetic eye conditions that lead to incurable blindness), and in the management of ocular surfaces and implants.

From reaching the settlement agreements, to fortifying our Board of Directors, to moving our RPE program decisively forward in the clinic, to developing our other ocular programs, the company is truly firing on all cylinders.  Moreover, I can state with utmost confidence that 2012 is going to be the most exciting time in the company’s history.

Thank you, as always, for your interest and support.

Gary Rabin
Chairman and CEO
Advanced Cell Technology, Inc.





Further Information
ACT has filed with the Securities and Exchange Commission (the “SEC”) a preliminary proxy statement in connection with its proposal to increase its authorized shares. ACT plans to file a definitive proxy statement with the SEC and mail such definitive proxy statement to stockholders of record on the record date for the meeting at which stockholders will be asked to adopt the amendment to the company’s certificate of incorporation to increase the company’s authorized shares. The company, Mr. Rabin and certain of its directors, executive officers and other members of management may, under SEC rules, be deemed “participants” in the solicitation of proxies from the company’s stockholders with respect to the proposed increase in the company’s authorized shares. INVESTORS AND STOCKHOLDERS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED INCREASE IN THE COMPANY’S AUTHORIZED SHARES ABOUT THE PROPOSAL AND OTHER IMPORTANT INFORMATION INCLUDING THOSE PERSONS WHO MAY BE DEEMED “PARTICIPANTS” IN THE SOLICITATION. Investors and stockholders may obtain a free copy of the definitive proxy statement when it becomes available, and other documents filed by us with the SEC, including the preliminary proxy statement, at the SEC’s web site at http://www.sec.gov. Free copies of the definitive proxy statement, when it becomes available, and the Company’s other filings with the SEC may also be obtained from the Company by directing a request to Advanced Cell Technology, Inc., 33 Locke Drive, Marlborough, Massachusetts 01752, Attention: Secretary.

Forward-Looking Statements
Statements in this document regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.
生命不息，战斗不止。
回复 引用

TOP

中级会员

Rank: 3Rank: 3
8#
友好网来发表于 2011-12-18 18:56 | 只看该作者
安全性是必须考虑的。
回复 引用

TOP

返回列表